A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis
- Conditions
- HIV InfectionsHistoplasmosisBlastomycosis
- Registration Number
- NCT00002159
- Lead Sponsor
- Janssen, LP
- Brief Summary
To assess the safety of intravenous itraconazole compared to amphotericin B in HIV positive or negative persons with blastomycosis or histoplasmosis.
- Detailed Description
Patients are randomized to receive IV itraconazole for 2 days, then either itraconazole daily for 5 days or amphotericin B daily for 7 days. IV treatment is followed by consolidation with oral itraconazole for up to 1 year.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
UAB Station / Infectious Division
🇺🇸Birmingham, Alabama, United States
Univ of Arkansas for Med Sciences
🇺🇸Little Rock, Arkansas, United States
Division of Infectious Diseases
🇺🇸Atlanta, Georgia, United States
Division of Inf Diseases/ Indiana Univ Hosp
🇺🇸Indianapolis, Indiana, United States
Community Hosp
🇺🇸Indianapolis, Indiana, United States
LSU Med Ctr / Div of Pulmonary & Critical Care Med
🇺🇸Shreveport, Louisiana, United States
Ann Arbor Veterans Administration Med Ctr
🇺🇸Ann Arbor, Michigan, United States
Univ of Missouri / Division of Infectious Diseases
🇺🇸Kansas City, Missouri, United States
Infectious Diseases Association / Research Med Ctr
🇺🇸Kansas City, Missouri, United States
UAB Station / Infectious Division🇺🇸Birmingham, Alabama, United States